Magazine article Clinical Psychiatry News

Lurasidone Favorably Affects Metabolic Syndrome

Magazine article Clinical Psychiatry News

Lurasidone Favorably Affects Metabolic Syndrome

Article excerpt

AT THE ECNP CONGRESS

BERLIN -- The prevalence of metabolic syndrome remained stable in outpatients with schizophrenia during 12 months of double-blind treatment with lurasidone, while the rate climbed significantly in those randomized to risperidone in a multicenter head-to-head comparative study.

The study included 611 outpatients with clinically stable schizophrenia who were randomized double blind 2:1 to 12 months of flexibly dosed oral lurasidone (Latuda) at 37-111 mg/day or to oral risperidone (Risperdal) at 2-6 mg/day.

The prevalence of metabolic syndrome at enrollment as defined by International Diabetes Federation criteria was 32.5% in the lurasidone group and virtually identical at 32.7% in the risperidone group.

After 1 year of double-blind treatment, 37% of those with baseline metabolic syndrome in the lurasidone group no longer met criteria for the metabolic derangement, compared with a 28% metabolic syndrome reversal rate in the risperidone group, Dr. John W Newcomer reported at the annual congress of the European College of Neuropsychopharmacology.

Among subjects without metabolic syndrome at baseline, the incidence of new-onset metabolic syndrome during 12 months of therapy was 16% with lurasidone, compared with 27% in those on risperidone. Thus, the 1-year on-treatment risk of developing metabolic syndrome was reduced by 48% in patients treated with lurasidone--as compared to risperidone-treated patients--observed Dr. Newcomer, a psychiatrist who serves as executive vice dean and professor of clinical biomedical science at the Florida Atlantic University College of Medicine in Boca Raton.

Patients on risperidone gained a mean of 2.6 kg over the course of the year, and those on lurasidone lost 0.9 kg. Mean waist circumference grew by 2.6 cm in the risperidone group, compared with a 0.4-cm decrease in the lurasidone group. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.